Japan’s Taiho Pharmaceutical and Toray Co-Develop Overactive Bladder Agent
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based Taiho Pharmaceutical and Toray March 11 started a joint development of beta-3-adrenoceptor agonist TRK-380/TAC-301 to treat overactive bladder. The two are preparing to start a Phase I trial in Japan. The agent works to relax bladder muscle and increase the bladder volume by stimulating the beta-3 adrenoreceptors. The details of the co-development agreement including payment are not disclosed. Taiho has set urology products a development priority. (Click here for more - Japanese language